TY - JOUR
T1 - Loss of transforming growth factor-β type II receptor gene expression in primary human esophageal cancer
AU - Garrigue-Antar, Laure
AU - Souza, Rhonda F.
AU - Vellucci, Vincent F.
AU - Meltzer, Stephen J.
AU - Reiss, Michael
PY - 1996/8
Y1 - 1996/8
N2 - Cell lines derived from carcinomas of the upper aero-digestive tract are typically refractory to transforming growth factor β-mediated cell cycle arrest. Recently, we reported that the type II transforming growth factor β receptor (TβR-II) gene can be inactivated on the basis of missense mutations in such cell lines. These findings prompted us to investigate the molecular status of the TβR-II gene in primary tumor specimens. Among 21 of 24 evaluable primary esophageal carcinomas, there were 6 cases (28.5%; 95% confidence interval, 11% to 52%) in which TβR-II transcripts were low or undetectable by a reverse transcription PCR assay. In one of these cases, we were able to ascribe the loss of TβR-II gene expression to high-density methylation of promoter sequences. We failed to detect any mutations within the open reading frame of the remaining tumors that expressed TβR-II mRNA. In this relatively small series of cases, loss of TβR-II expression was independent of pathologic tumor stage, histologic subtype, or outcome of patients with esophageal cancer. Thus, loss of expression of the TβR-II gene appears to be the predominant mechanism through which this gene is inactivated in esophageal cancer.
AB - Cell lines derived from carcinomas of the upper aero-digestive tract are typically refractory to transforming growth factor β-mediated cell cycle arrest. Recently, we reported that the type II transforming growth factor β receptor (TβR-II) gene can be inactivated on the basis of missense mutations in such cell lines. These findings prompted us to investigate the molecular status of the TβR-II gene in primary tumor specimens. Among 21 of 24 evaluable primary esophageal carcinomas, there were 6 cases (28.5%; 95% confidence interval, 11% to 52%) in which TβR-II transcripts were low or undetectable by a reverse transcription PCR assay. In one of these cases, we were able to ascribe the loss of TβR-II gene expression to high-density methylation of promoter sequences. We failed to detect any mutations within the open reading frame of the remaining tumors that expressed TβR-II mRNA. In this relatively small series of cases, loss of TβR-II expression was independent of pathologic tumor stage, histologic subtype, or outcome of patients with esophageal cancer. Thus, loss of expression of the TβR-II gene appears to be the predominant mechanism through which this gene is inactivated in esophageal cancer.
UR - http://www.scopus.com/inward/record.url?scp=0029762628&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029762628&partnerID=8YFLogxK
M3 - Article
C2 - 8765326
AN - SCOPUS:0029762628
SN - 0023-6837
VL - 75
SP - 263
EP - 272
JO - Laboratory Investigation
JF - Laboratory Investigation
IS - 2
ER -